Gujarat Themis Biosyn Ltd vs Marksans Pharma Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 05, 2026

Key Highlights

The Latest Trading Price of Gujarat Themis Biosyn Ltd is ₹ 383.9 as of 05 May 16:01 . The P/E Ratio of Gujarat Themis Biosyn Ltd changed from 0 on March 2021 to 0 on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe P/E Ratio of Marksans Pharma Ltd changed from 8.7 on March 2021 to 26.5 on March 2025 . This represents a CAGR of 24.95% over 5 years The Market Cap of Gujarat Themis Biosyn Ltd changed from ₹ 0 crore on March 2021 to ₹ 0 crore on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Market Cap of Marksans Pharma Ltd changed from ₹ 2044 crore on March 2021 to ₹ 10076 crore on March 2025 . This represents a CAGR of 37.58% over 5 years The revenue of Gujarat Themis Biosyn Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 revenue of ₹ 0 crore. This represent the decline of 0% The revenue of Marksans Pharma Ltd for the Dec '25 is ₹ 774.57 crore as compare to the Sep '25 revenue of ₹ 741.98 crore. This represent the growth of 4.39% The ebitda of Gujarat Themis Biosyn Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 ebitda of ₹ 0 crore. This represent the decline of 0% The ebitda of Marksans Pharma Ltd for the Dec '25 is ₹ 180.89 crore as compare to the Sep '25 ebitda of ₹ 166.07 crore. This represent the growth of 8.92% The net profit of Gujarat Themis Biosyn Ltd changed from ₹ 0 crore to ₹ 0 crore over 7 quarters. This represents a CAGR of 0.0% The net profit of Marksans Pharma Ltd changed from ₹ 89.07 crore to ₹ 113.69 crore over 7 quarters. This represents a CAGR of 14.97% The Dividend Payout of Gujarat Themis Biosyn Ltd changed from 36.62 % on March 2022 to 14.97 % on March 2025 . This represents a CAGR of -20.04% over 4 yearsThe Dividend Payout of Marksans Pharma Ltd changed from 10.4 % on March 2021 to 19.26 % on March 2025 . This represents a CAGR of 13.12% over 5 years .

About Gujarat Themis Biosyn Ltd

Promoted byJayshree D Patel, Gujarat Themis Biosyn Limited (GTBL) was incorporated in 1981 as a joint sector company with Gujarat Industrial Investment Corporation Ltd (GIIC) and Chemosyn (P) Ltd. The Company commenced production in August 1985.
It was subsequently taken over in June 1991 by Yuhan Group, South Korea and Pharmaceutical Business Group (India) Ltd. (PBG); a unique consortium of five competing drug companies - Themis Medicare Ltd., Kopran Ltd., Anant & Co., Cadila Health Care Ltd. (Zydus) and Lyka Labs Ltd. It is actively managed by Themis Medicare Ltd. (JV company of Gedeon Richter Ltd, Hungary) since 2007. Initially manufacturing the antibiotic, erythromycin, GTBL obtained licences to manufacture bulk drugs like rifampicin, cephalexin, griseofulvin and their formulations in 1990.

About Marksans Pharma Ltd

Marksans Pharma Limited was formerly incorporated as 'Tasc Pharmaceuticals Limited' in April, 1982.
Pursuant to the Scheme of Amalgamation, name of the Company was changed from Tasc Pharmaceuticals Limited to Marksans Pharma Limited from 10th October, 2005.
The Company primarily engaged in the business of research, manufacture, marketing and sale of pharmaceutical formulation.
The Company's research and development facilities are located in Verna, Goa and R & D center in Navi Mumbai. In 2004-05, the Company amalgamated with M/s.
Marksans Pharma Limited (formerly M/s.

FAQs for the comparison of Gujarat Themis Biosyn Ltd and Marksans Pharma Ltd

Which company has a larger market capitalization, Gujarat Themis Biosyn Ltd or Marksans Pharma Ltd?

Market cap of Gujarat Themis Biosyn Ltd is 4,063 Cr while Market cap of Marksans Pharma Ltd is 8,558 Cr

What are the key factors driving the stock performance of Gujarat Themis Biosyn Ltd and Marksans Pharma Ltd?

The stock performance of Gujarat Themis Biosyn Ltd and Marksans Pharma Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Gujarat Themis Biosyn Ltd and Marksans Pharma Ltd?

As of May 5, 2026, the Gujarat Themis Biosyn Ltd stock price is INR ₹372.95. On the other hand, Marksans Pharma Ltd stock price is INR ₹188.85.

How do dividend payouts of Gujarat Themis Biosyn Ltd and Marksans Pharma Ltd compare?

To compare the dividend payouts of Gujarat Themis Biosyn Ltd and Marksans Pharma Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.